IDH2 and acute myeloid leukemia: In our Mayo clinic experience with venetoclax plus HMA as salvage therapy in relapsed AML exclusive of post-transplant relapse (n = 42), we observed CR/CRi rates of 33%, with similar responses across the mutational spectrum; FLT3 (50%), IDH2 (60%), RUNX1 (75%), and TP53 (40%) mutated patients.